Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CDw75 encodes a member of glycosyltransferase family 29.
Showing 8 out of 12 products:
Suggest a crucial role for ST6Gal1 (show ST6GAL1 Antibodies) in elevating the invasiveness of pancreatic ductal adenocarcinoma cells in a fructose-responsive manner.
these results indicate that ST6Gal-I (show ST6GAL1 Antibodies) plays a critical role in cell proliferation and invasion via the PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies)/GSK-3beta/beta-catenin (show CTNNB1 Antibodies) signaling pathway during cancer progression
these results indicate that ST6Gal-I (show ST6GAL1 Antibodies) might play a positive role in mediating the survival of human hepatocarcinoma cells
The results demonstrate that epigenetic modulation of ST6Gal1 (show ST6GAL1 Antibodies) expression plays a key role in the glioma phenotype in vitro and that that therapeutic approaches targeting elements of the epigenetic machinery for the treatment of human glioblastoma are warranted.
The data confirm that circulatory ST6Gal-1 (show ST6GAL1 Antibodies) is a negative systemic regulator of granulopoiesis
Results provide evidence that ST6GAL1 (show ST6GAL1 Antibodies) contributes to drug resistance in cervical neoplasm.
High ST6GAL1 (show ST6GAL1 Antibodies) expression is associated with ovarian and pancreatic Cancers.
ST3Gal I (show ST3GAL1 Antibodies) and ST6Gal I (show ST6GAL1 Antibodies) have different sialic acid donor specificity.
Taken together, these results indicate a dynamic change in the expression of ST6GAL1 (show ST6GAL1 Antibodies) during the CRC (show CALR Antibodies) progression and provide a list of sialylated proteins potentially relevant to the different functions of ST6GAL1 (show ST6GAL1 Antibodies) in CRC (show CALR Antibodies).
The results presented in this study provide an important advance by highlighting a new function for ST6Gal-I (show ST6GAL1 Antibodies) in promoting the viability of tumor cells exposed to the type of serum-depleted conditions often found in hypovascularized tumor microenvironments.
This gene encodes a member of glycosyltransferase family 29. The encoded protein is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates. The protein, which is normally found in the Golgi but can be proteolytically processed to a soluble form, is involved in the generation of the cell-surface carbohydrate determinants and differentiation antigens HB-6, CD75, and CD76. This gene has been incorrectly referred to as CD75. Three transcript variants encoding two different isoforms have been described.
B-cell antigen CD75
, CMP-N-acetylneuraminate beta-galactosamide alpha-2,6-sialyltransferase
, CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1
, ST6Gal I
, alpha 2,6-ST 1
, beta-galactoside alpha-2,6-sialyltransferase 1
, sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase)